# LBH589 (Panobinostat) for the Treatment of Myelofibrosis

> **NCT01298934** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ronald Hoffman** · enrollment: 22 (actual)

## Conditions studied

- Primary Myelofibrosis
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Post-Essential Thrombocythemia Related Myelofibrosis

## Interventions

- **DRUG:** LBH589

## Key facts

- **NCT ID:** NCT01298934
- **Lead sponsor:** Ronald Hoffman
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298934, "LBH589 (Panobinostat) for the Treatment of Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01298934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*